Parallel Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Parallel Advisors’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-796	Closed	-$3.25K	–	3557
2023 Q1	$3.25K	Buy	796 +753	+1,751%	+$3.48K	﹤0.01%	2575
2022 Q4	$216	Buy	43 +18	+72%	+$113	﹤0.01%	3177
2022 Q3	$0	Sell	25 -23	-48%	-$348	﹤0.01%	3587
2022 Q2	$1K	Buy	+48	New	+$665	﹤0.01%	2910
2022 Q1	–	Sell	-112	Closed	-$2K	–	3356
2021 Q4	$2K	Sell	112 -90	-45%	-$1.73K	﹤0.01%	2783
2021 Q3	$4K	Buy	+202	New	+$4.45K	﹤0.01%	2520

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Parallel Advisors's NGM Position: Q2 2023 in Review

Parallel Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 796 shares — an estimated $3.25K sold.

Parallel Advisors first reported a position in NGM in Q3 2021 and held it in 6 quarters. The position peaked at $4K in Q3 2021. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

Parallel Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Parallel Advisors sold 796 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $3.25K.
Parallel Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
Parallel Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $4K in Q3 2021.
106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Parallel Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.